Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush… - Antimicrobial agents …, 2021 - Am Soc Microbiol
ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
[HTML][HTML] Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
YC Chang, YC Chen, CC Huang, CM Fu, YT Lee… - International Journal of …, 2023 - Elsevier
Background Molnupiravir is an essential oral antiviral agent against coronavirus disease
2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients …
2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients …
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19： a meta-analysis
W Wen, C Chen, J Tang, C Wang, M Zhou… - Annals of …, 2022 - Taylor & Francis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …
controlled. Although great achievements have been made in COVID-19 research and many …
The role of antiviral treatment in the COVID-19 pandemic
TK Burki - The Lancet Respiratory Medicine, 2022 - thelancet.com
On Dec 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …
[HTML][HTML] Making statistical sense of the molnupiravir MOVe-OUT clinical trial
K Thorlund, K Sheldrick… - The American Journal …, 2022 - ncbi.nlm.nih.gov
Oral therapies for the early treatment of COVID-19 may prevent disease progression and
health system overcrowding. A new oral therapeutic named molnupiravir has been …
health system overcrowding. A new oral therapeutic named molnupiravir has been …
[HTML][HTML] Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis
T Pitre, R Van Alstine, G Chick, G Leung, D Mikhail… - Cmaj, 2022 - Can Med Assoc
Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …
[HTML][HTML] Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients
P Poznański, H Augustyniak-Bartosik, A Magiera-Żak… - Viruses, 2022 - mdpi.com
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
[HTML][HTML] Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
S Singla, S Goyal - Bulletin of the National Research Centre, 2022 - Springer
Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …
Why molnupiravir fails in hospitalized patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or …
Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …